ResultsIQ

ResultsIQ › Latest results › Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited Q1 FY27 results press release summary

NSE: APLLTD · BSE: 533573

Results press release of 4 Aug 2026, summarised by AI from the filing.

Alembic Pharmaceuticals Q1 FY27 revenue ₹2150 cr, up 26% YoY, with PAT ₹173 cr and EBITDA pre R&D margin 24%.

Key takeaways

  1. Revenue Q1 FY27 revenue from operations ₹2150 cr, up 26% YoY.
  2. PAT Q1 FY27 profit after tax ₹173 cr, up 12% YoY.
  3. EBITDA Q1 FY27 EBITDA pre R&D ₹523 cr; margin 24%.
  4. US business US Formulation revenue ₹778 cr, up 49% YoY, with 7 launches and 10 ANDA approvals.
  5. India business India Branded Business revenue ₹642 cr, up 7% YoY, with 3 new products introduced.

Original filing on BSE

Alembic Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹2,150 cr (+26% year on year), EBITDA ₹332 cr (+18% year on year), PAT ₹172 cr (+12% year on year), EBITDA margin 15.4% (−104 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,848 cr (+4% year on year), EBITDA ₹228 cr (−17% year on year), PAT ₹202 cr (−26% year on year), EBITDA margin 12.3% (−309 bps). Score 9 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 309 bps year on year. Tax rate -71%. Profit fell 31% from last quarter. Share price after the results: −5.4% in 28 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹1,876 cr (+11% year on year), EBITDA ₹294 cr (+13% year on year), PAT ₹132 cr (+16% year on year), EBITDA margin 15.6% (+34 bps). Score 46 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit before exceptional items growth were in line with it. EBITDA margin rose 34 bps year on year. Consolidated profit -4% but standalone +33%. Profit fell 7% from last quarter. Share price after the results: −11.3% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹1,910 cr (+16% year on year), EBITDA ₹315 cr (+31% year on year), PAT ₹184 cr (+20% year on year), EBITDA margin 16.5% (+193 bps). Score 84 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin rose 193 bps year on year. Profit rose ₹31.0 cr on a year ago, more than the ₹16.0 cr it added the year before. Share price after the results: −2.4% in 30 days (Nifty 500: −0.3%).
  • Q1 FY26: Revenue ₹1,711 cr (+10% year on year), EBITDA ₹282 cr (+19% year on year), PAT ₹154 cr (+14% year on year), EBITDA margin 16.5% (+131 bps). Score 60 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 131 bps year on year. Consolidated profit +14% but standalone -41%. Revenue fell 3% from last quarter. Profit rose ₹19.0 cr on a year ago, more than the ₹14.0 cr it added the year before. Share price after the results: −0.7% in 30 days (Nifty 500: −0.2%).
  • Q4 FY25: Revenue ₹1,770 cr (+17% year on year), EBITDA ₹273 cr (+5% year on year), PAT ₹157 cr (−12% year on year), EBITDA margin 15.4% (−165 bps). Score 55 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 165 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +7.5% in 30 days (Nifty 500: +3.3%).
  • Q3 FY25: Revenue ₹1,693 cr (+4% year on year), EBITDA ₹259 cr (−3% year on year), PAT ₹138 cr (−23% year on year), EBITDA margin 15.3% (−101 bps). Score 18 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 101 bps year on year. Profit fell 10% from last quarter.
  • Q2 FY25: Revenue ₹1,648 cr (+3% year on year), EBITDA ₹240 cr (+15% year on year), PAT ₹153 cr (+12% year on year), EBITDA margin 14.6% (+146 bps). Score 49 of 100, In line with trend. EBITDA margin rose 146 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Alembic Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.